2seventy bio, Inc. (TSVT)

NASDAQ: TSVT · IEX Real-Time Price · USD
4.455
+0.055 (1.25%)
May 24, 2024, 10:05 AM EDT - Market open
1.25%
Market Cap 227.98M
Revenue (ttm) 71.20M
Net Income (ttm) -223.22M
Shares Out 51.41M
EPS (ttm) -4.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,776
Open 4.390
Previous Close 4.400
Day's Range 4.310 - 4.480
52-Week Range 1.535 - 12.690
Beta 1.87
Analysts Buy
Price Target 10.67 (+139.51%)
Earnings Date May 8, 2024

About TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 274
Stock Exchange NASDAQ
Ticker Symbol TSVT
Full Company Profile

Financial Performance

In 2023, 2seventy bio's revenue was $100.39 million, an increase of 9.72% compared to the previous year's $91.50 million. Losses were -$217.57 million, -14.39% less than in 2022.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for TSVT stock is "Buy." The 12-month stock price forecast is $10.67, which is an increase of 139.51% from the latest price.

Price Target
$10.67
(139.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

2seventy bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annua...

1 day ago - Business Wire

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024. “In the first quarter of 2024, ...

16 days ago - Business Wire

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:0...

21 days ago - Business Wire

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms ...

7 weeks ago - Business Wire

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Offi...

2 months ago - Business Wire

2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quar...

2 months ago - Business Wire

2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webc...

3 months ago - Business Wire

2seventy bio to sell experimental cell therapies to Regeneron

Cancer treatment maker 2seventy bio will sell all its experimental cell therapies to Regeneron Pharmaceuticals for an upfront payment of $5 million and focus on its sole approved product Abecma, the t...

Other symbols: REGN
4 months ago - Reuters

2seventy bio Announces New Strategic Path Forward

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (ideca...

4 months ago - Business Wire

2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December ...

5 months ago - Business Wire

2seventy bio Reiterates Commitment to Maximizing Shareholder Value

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating it...

6 months ago - Business Wire

Engine Capital pushes for changes at cancer therapy developer 2seventy bio

Activist investor Engine Capital on Wednesday sent a letter to the board of cancer therapy developer 2seventy bio , urging a board refresh and the appointment of its chief operating officer Chip Baird...

6 months ago - Reuters

Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value

NEW YORK--(BUSINESS WIRE)--Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (Nasdaq: TSVT) (“2seventy” or the “Company”) outstanding shares, today announced that it sent the belo...

6 months ago - Business Wire

Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug

Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for...

Other symbols: BMY
6 months ago - Investopedia

Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment

Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential appro...

Other symbols: BMY
6 months ago - Market Watch

US FDA delays decision on Bristol Myers-2seventy bio cancer therapy

The U.S. Food and Drug Administration (FDA) will not make a decision on Bristol Myers Squibb and 2seventy bio's marketing application of their blood cancer therapy, Abecma, for earlier lines of treatm...

Other symbols: BMY
6 months ago - Reuters

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the third quarter ended...

6 months ago - Business Wire

2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 20...

7 months ago - Business Wire

2seventy bio to lay off 40% of workforce

2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma.

9 months ago - Reuters

2seventy bio cutting 176 jobs, search for new chief executive

2seventy bio Inc. stock TSVT, -6.81% rose 2.7% in premarket trading on Tuesday after the T-cell drug company for cancer treatment said it's cutting 176 jobs or 40% of its work force and launching a se...

9 months ago - Market Watch

2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a restructuring of its business operations and research and development model to significantly reduce costs while ...

9 months ago - Business Wire

2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies

CAMBRIDGE, Mass. & SHANGHAI, China--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative ...

9 months ago - Business Wire

2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will participate in a fireside...

9 months ago - Business Wire

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the second quarter ende...

10 months ago - Business Wire

2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023...

10 months ago - Business Wire